S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

NYSE:DGXQuest Diagnostics Stock Price, Forecast & News

$122.71
+3.63 (+3.05 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$118.80
Now: $122.71
$122.75
50-Day Range
$104.55
MA: $114.22
$122.61
52-Week Range
$73.02
Now: $122.71
$125.00
Volume2.18 million shs
Average Volume1.23 million shs
Market Capitalization$16.41 billion
P/E Ratio21.12
Dividend Yield1.92%
Beta1.38
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More
Quest Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 1.7Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.02 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.73 billion
Cash Flow$9.55 per share
Book Value$42.22 per share

Profitability

Net Income$858 million

Miscellaneous

Employees47,000
Market Cap$16.41 billion
Next Earnings Date7/28/2020 (Estimated)
OptionableOptionable

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

How has Quest Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Quest Diagnostics' stock was trading at $99.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DGX stock has increased by 23.0% and is now trading at $122.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Quest Diagnostics?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Quest Diagnostics.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Quest Diagnostics.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) issued its earnings results on Wednesday, April, 22nd. The medical research company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.06. The medical research company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.76 billion. Quest Diagnostics had a return on equity of 14.79% and a net margin of 10.36%. Quest Diagnostics's revenue was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.40 EPS. View Quest Diagnostics' earnings history.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Monday, May 18th. Stockholders of record on Wednesday, July 8th will be given a dividend of $0.56 per share on Wednesday, July 22nd. This represents a $2.24 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date of this dividend is Tuesday, July 7th. View Quest Diagnostics' dividend history.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its second quarter 2020 Pre-Market earnings guidance on Monday, July, 13th. The company provided earnings per share (EPS) guidance of 1.39-1.42 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.12. The company issued revenue guidance of $1.83-1.83 billion, compared to the consensus revenue estimate of $1.52 billion.

What price target have analysts set for DGX?

19 equities research analysts have issued 12-month price objectives for Quest Diagnostics' shares. Their forecasts range from $85.00 to $146.00. On average, they expect Quest Diagnostics' share price to reach $118.84 in the next twelve months. This suggests that the stock has a possible downside of 3.2%. View analysts' price targets for Quest Diagnostics.

What are Wall Street analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:
  • 1. According to Zacks Investment Research, "Quest Diagnostics reported a strong fourth quarter with both earnings and revenues beating the respective Zacks Consensus Estimate. Revenues for Diagnostic Information Services grew on strong volume growth, an easy comparable and acquisitions amid significant reimbursement pressure related to PAMA. We are upbeat about the company’s expanded network access, which helped accelerate volume growth in the quarter. The current-year outlook seems promising despite the company’s having reckoned another year of meaningful reimbursement. Quest Diagnostics has outperformed its industry over the past six months. On the flip side, the company is currently facing several PAMA-related reimbursement issues and pricing pressure. This apart, escalating costs and a tough competitive landscape are concerns." (3/16/2020)
  • 2. Evercore ISI analysts commented, "We spent time on the west coast last week (LA + SF weather right now >>> Diagnostics (CFO and IR). Post solid 1H results after a reset in sentiment, numbers, and multiples last year, it is safe to say investor perception has recovered somewhat and the focus has shifted back towards the longer term path with the possibility of regulatory easing (particularly as organic volumes surprised last Q)." (8/8/2019)

Has Quest Diagnostics been receiving favorable news coverage?

Media stories about DGX stock have trended somewhat negative on Tuesday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Quest Diagnostics earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Quest Diagnostics.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 3,290,000 shares, a decrease of 16.1% from the June 15th total of 3,920,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is currently 1.7 days. Approximately 2.5% of the company's stock are short sold. View Quest Diagnostics' Current Options Chain.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Endologix (ELGX), Micron Technology (MU), Gilead Sciences (GILD), Chipotle Mexican Grill (CMG), Procter & Gamble (PG), Cisco Systems (CSCO) and QUALCOMM (QCOM).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.16%), Sabal Trust CO (0.14%), Gradient Investments LLC (0.07%), DNB Asset Management AS (0.06%), First Financial Bank Trust Division (0.06%) and Toth Financial Advisory Corp (0.04%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski. View institutional ownership trends for Quest Diagnostics.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., DNB Asset Management AS, State of Alaska Department of Revenue, Sabal Trust CO, Manning & Napier Group LLC, IFM Investors Pty Ltd, Lake Street Financial LLC, and Wedge Capital Management L L P NC. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Michael E Prevoznik, Michael J Deppe, and Stephen H Rusckowski. View insider buying and selling activity for Quest Diagnostics.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was purchased by a variety of institutional investors in the last quarter, including Gradient Investments LLC, Patton Fund Management Inc., First Financial Bank Trust Division, MERIAN GLOBAL INVESTORS UK Ltd, Cypress Capital Group, O Keefe Stevens Advisory Inc., Keudell Morrison Wealth Management, and Redhawk Wealth Advisors Inc.. View insider buying and selling activity for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $122.71.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $16.41 billion and generates $7.73 billion in revenue each year. The medical research company earns $858 million in net income (profit) each year or $6.56 on an earnings per share basis. Quest Diagnostics employs 47,000 workers across the globe.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.